#5 - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE: JNJ) Another great low-risk investment strategy is to buy what you know. Or maybe put another way, buy what you know you, or others, are buying. That idea of reaching customers at a variety of touch points is one of the reasons it has an outstanding business model. JNJ is known for its consumer products, but also operates businesses in 60 countries with products that provide diverse revenue streams in the areas of consumer products, pharmaceutical, and medical devices. Like other low-risk stocks, Johnson & Johnson is a defensive stock. There’s a reason health care remains on the front burner of our national conversation. People get sick and so JNJ’s products will have a customer base regardless of the market. And most of those purchases will be steady, repeat purchases which helps provide them with a consistent revenue stream. Johnson & Johnson is also one of only two companies that maintains a AAA credit rating. This gives it access to low-cost debt that they can pour into R&D, marketing and other acquisitions that fuel growth while still maintaining a solid free cash flow that allows them to return cash to shareholders. To that end, J&J is considered a dividend aristocrat returning a dividend that has increased for 54 years.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $155.17
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 8 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $175.94 (13.4% Upside)
